Purpose: To evaluate prospectively the role and impact of multidetector row computed tomography (MDCT) before bronchial artery embolization (BAE) in patients with hemoptysis. Methods: MDCT of the thorax was performed in 27 patients (21 men, 6 women; age range, 22-70 years; mean, 39 years) with hemoptysis who were referred for BAE. Transverse, multiplanar reconstruction, and 3-dimensional reconstruction (maximum intensity projection and volume rendered) images were analysed to identify the abnormal hypertrophied bronchial and nonbronchial systemic arteries causing hemoptysis, their origin and course were noted. Digital subtraction angiography was performed with the knowledge of findings of MDCT. Selective arteriogram of abnormal bronchial as well as nonbronchial arteries was performed. Embolization was attempted in 25 of these patients (92.6%) by using polyvinyl alcohol particles (350-500 mm), Gelfoam or Embospheres (400-700 mm). Follow-up was done for a mean period of 20.5 months. Results: Based on MDCT, 2 of 27 patients were found unsuitable for BAE. On computed tomography, 38 arteries (27 bronchial and 11 nonbronchial systemic arteries) were identified as abnormal hypertrophied vessels. On angiography, 34 of these arteries (25 bronchial and 9 nonbronchial systemic arteries) were found to be responsible for hemoptysis. Three of these arteries could not be evaluated during angiography, and 1 artery that was identified as abnormal on computed tomography was found normal on angiography. All 25 bronchial and 9 nonbronchial systemic arteries that cause hemoptysis were detected at MDCT. Embolization was successful in 23 of 25 patients. Conclusion: MDCT enables detection and depiction of all bronchial and nonbronchial systemic arteries causing hemoptysis.
Hemoptysis is a common respiratory problem and can occur due to a wide variety of causes. Common causes of hemoptysis are tuberculosis (either active or its sequelae), bronchiectasis (due to other causes), aspergilloma, and bronchogenic carcinoma. In situations in which surgery will eliminate the cause of hemoptysis, it is the treatment of choice. However, many of these patients are not surgical candidates due to diffuse pulmonary disease, poor pulmonary reserves, or poor general condition. Moreover, surgical management in the acute situation is associated with high mortality and high morbidity.
In 1973, Remy et al [1] performed the first bronchial artery embolization (BAE) for the control of hemoptysis. Since then, BAE has found widespread acceptance as a measure to control hemoptysis in inoperable cases or in patients who are unstable before surgery. Although BAE is commonly used for treating massive hemoptysis, chronic recurrent mild and recurrent hemoptysis, which disturbs the life style of the patient and is not amenable to surgical treatment, also is increasingly being treated with BAE.
In patients with an episode of hemoptysis, rapid identification of the site and the cause of bleeding with noninvasive imaging techniques before the use of interventional procedures is important. Diagnostic studies for massive hemoptysis include radiography, bronchoscopy, and CT of the chest. Introduction of helical CT with dynamic contrast-enhanced study led to many studies in the past years to depict the site of bleeding as well as identification of abnormal bronchial ateries [2] . However, more recently, after the advent of MDCT, various retrospective studies [3e5] have shown the utility of MDCT CT angiography (CTA), but no prospective studies exist. CTA is currently the standard of care in the management of patients with hemoptysis [6] . Therefore, the utility of this current study is to prospectively validate what has evolved into the current standard of care. to show the usefulness of the information provided by MDCT in therapeutic decisions in patients with hemoptysis. So, we undertook this prospective study to show the clinical impact of MDCT in patients with hemoptysis.
Material and Methods
As per the following inclusion and exclusion criteria, 27 patients who presented with massive, moderate, or recurrent hemoptysis, and were referred to our department for BAE were included in this study. These patients were assessed by using MDCT before digital subtraction angiography (DSA) and BAE. Institutional ethical committee approval was not obtained because it was not mandatory at that point of time. However, ethical clearance was obtained from a departmental committee, and informed consent was obtained from every patient.
Inclusion criteria were the following: (1) patients with severe hemoptysis defined as blood loss more than 300 mL/d or more, or (2) patients with recurrent bouts of moderate hemoptysis defined as 3 or more bouts of blood loss of more than 100 mL/d within a week, or (3) patients with chronic recurrent small-volume (<100 mL/d) hemoptysis that interfered with the patient's lifestyle and/or prevents effective physical therapy. Patients who were good surgical candidates with resectable lesion, those for whom angiography was contraindicated (eg, contrast allergy, renal function abnormalities, bleeding diathesis), and patients <18 years of age were excluded from the study.
At the time of first contact with the patient, a detailed history was obtained. The amount of blood expectorated in the last 48 hours was recorded. In the patient with recurrent hemoptysis, a history was taken, inquiring about the number of episodes in the past 6 months and the amount of blood expectorated in each episode.
MDCT was performed with a 4-row detector CT scanner (volume zoom; 140 kV, 60-100 mAs, rotation time of 0.5 second, 1-mm collimation; Siemens Medical Solutions, Erlangen, Germany) in 22 patients and with a 16edetector row scanner (140 kV, 70-120 mAs, rotation time of 0.5 second, 0.75-mm collimation; Sensation 16 [Siemens]) in the remaining 5 patients. All the patients underwent caudocranial scanning in a supine position at end inspiratory suspension during a single breath hold. All the patients received 70-100 mL (total 30 g) of nonionic contrast material with 300 mg of iodine per milliliter, which was administered intravenously into the antecubital vein through an 18-gauge catheter at a rate of 3.5 mL/s by using an automated injector. Scan delay time was chosen between 18-24 seconds in a 4edetector row scanner. For the 16edetector row scanner, the automatic bolus triggering software program was systematically applied, with a circular region of interest positioned at the level of the descending thoracic aorta just below the carina and a threshold for triggering data acquisition preset at 100 HU. Acquisition was performed from the thoracicinlet to the lower border of L2 level to include celiac and phrenic arteries. For CTA reconstruction was done at 1-mm slice thickness, with 0.6-mm increment. Reconstruction was done in maximum intensity projection, multiplanar reformation, and 3-dimensional volume rendered (VR) images.
CT Analysis
First, CT was analysed to look for the cause of hemoptysis and to localize the site of hemoptysis. Images were viewed in the lung and mediastinal window to look for parenchymal changes, any lymphadenopathy, pleural thickening, and major vessels.
Analysis of Bronchial Arteries
CT interpretation was done by using axial images, multiplanar reformation images, and 3-dimensional reconstructions (maximum intensity projection and VR) images to identify bronchial arteries, and the following parameters were recorded: (a) the total number of bronchial arteries per side; (b) the site of the ostium of the bronchial artery (or arteries); (c) location of the ostium on the wall of the descending aorta (ie, posterior, medial, anterior, or lateral), and its position relative to the tracheal carina, (d) bronchial artery diameter; (e) visualized course of bronchial arteries.
Bronchial arteries were considered abnormal when (a) the diameter of the bronchial artery was 2 mm, or (b) the course of the bronchial artery was visualized up to the hilum. The bronchial artery that satisfied either or both of these criteria was considered an abnormal hypertrophied artery and as a source of hemoptysis.
The origin of bronchial artery was considered orthotopic when the origin was from the descending aorta between the levels of the T5 and T6 vertebrae and ectopic when identified at a level of the descending aorta other than the expected origin (ie, outside levels T5-T6) or from any aortic branch vessel.
Analyses of Nonbronchial Systemic Arteries
Arteries that enter the lung parenchyma through the inferior pulmonary ligament or through the adherent pleura and with trajectories that are not parallel to the bronchi are considered as nonbronchial arteries. They were considered abnormal when they become dilated and tortuous, and were seen within extrapleural fat in association with pleural thickening (3 mm) and/or lung parenchyma abnormalities. Whenever an abnormal nonbronchial systemic artery was identified, its origin and course was noted.
Angiography and Embolization
In all the patients, DSA was performed within a median period of 5 days (range, 0-25 days) after CT, depending upon the clinical condition of the patient; 70-120 mL of nonionic (iohexol [Omnipaque; GE Healthcare, Princeton, NJ]) contrast agent was used in all the patients. A preliminary flush thoracic aortogram was performed to identify the bronchial arteries and systemic collaterals. We noted the number, origin, and course of bronchial arteries visualized on flush aortogram.
Angiographic procedures were performed with the knowledge of CT findings. Flush aortogram was followed by selective bronchial artery catheterization. For selective bronchial engagement, 5F/4F curved catheters such as the Simmons, celiac, picard, and renal double curve were used, and microcatheters were used when required. Arteriography also was done for nonbronchial systemic arteries when required. Abnormal bronchial arteries and nonbronchial systemic arteries were embolized. Embolic materials used were the following: polyvinyl alcohol (PVA) (size, 350-550 mm; Boston Scientific Ireland Ltd, Galway, Ireland, or Cook Medical, Bloomington, IN), Gelfoam and Embosphere (size, 500-700 mm; Biosphere Medical S A, Etoile; Roissy on France, UK). Gelfoam was never used as the only embolic agent in any of the patients.
The following angiographic findings were considered to be predictive of the vessels responsible for hemoptysis: (a) tortuous enlargement of bronchial and/or nonbronchial systemic arteries that supplied the area of parenchymal staining, and (b) a shunt into pulmonary vessels. The results of angiography were compared with the results of MDCT.
Follow-up
Follow-up was done for a mean of 20.5 months to know about any recurrent bout of hemoptysis by clinical assessment. Follow-up CT also was performed in 1 patient to follow up a small subintimal dissection that occurred during the embolization procedure.
Results
In the study population, the most common cause of hemoptysis was sequelae of prior tuberculous infection (51.8%). Five of these patients also had aspergillomas. The second most-frequent cause was bronchiectasis (22.2%) due to another cause. Twenty-four patients (88.9%) presented with either massive or recurrent moderate hemoptysis.
CTA

Bronchial arteries
In this study, we found 27 abnormal bronchial arteries (17 right bronchial arteries and 10 left bronchial arteries). The diameter of the abnormal right bronchial arteries ranged from 2.2-4.3 mm (mean, 2.9 mm) ( Figure 1 ). The diameter of abnormal left bronchial arteries ranged from 2-5 mm (mean, 2.9 mm) ( Figures 2-4 ). Among the 27 abnormal bronchial arteries, the origin of 17 (63%) were found to be at the T5 level. An important observation was that MDCT detected 2 abnormal arteries (7.4%) with ectopic origin, that is, at a level other than T5 or T6 ( Figure 5 ). Among right bronchial arteries, the origin of 16 arteries (94.2%) was found from the medial wall of the aorta, whereas the left bronchial was found to arise most commonly from the anterior wall (70.0%) of the aorta.
Nonbronchial systemic arteries
In addition to the bronchial arteries, MDCT also identified nonbronchial systemic arteries in 11 of 27 patients (40.7%). Among these 11 patients, 10 (90.9%) had pleural thickening ( Figures 6, 7 ). Only 1 patient with abnormal nonbronchial artery had normal pleura. This patient was diagnosed to have an unusual cause of hemoptysis, that is, an aberrant vessel supplying a normal segment of the left lower lobe (type 1 Pryce intralobar sequestration) ( Figure 8 ). Among the 11 patients with abnormal nonbronchial systemic arteries, 3 patients (11.1%) had normal bronchial arteries, and the nonbronchial systemic arteries were the only source of hemoptysis.
After the preprocedural evaluation by MDCT, 25 patients, of a total of 27 patients, were selected for BAE. The reasons for not performing BAE in 2 patients were as follows. The first patient had a history of wedge resection of the left upper lobe for hemoptysis. A diagnosis of fibrosis of the left upper lobe was made with high-resolution CT (HRCT) of the lung at that time. After MDCT and CTA, we made the diagnosis of an anomalous vessel supplying the segment of the left lower lobe (type 1 Pryce intralobar sequestration). The cause of hemoptysis in this condition is focal pulmonary hypertension, and embolization of abnormal vessel may actually worsen the hemoptysis. Surgery is considered to be the suitable treatment for this condition. Embolization was not performed. DSA was performed in this patient only for diagnostic purpose.
The second patient in whom embolization was not performed, came with the diagnosis of right lower lobe fibrosis based on his previous chest radiograph and HRCT of the lung. After MDCT and CTA, the diagnosis of chronic pulmonary thromboembolism that involved the right descending pulmonary artery with systemic to pulmonary collaterals was made ( Figure 9 ). The cause of hemoptysis in this condition was pulmonary infarctions or the breakdown of systemic pulmonary collaterals. Embolization of the systemic supply may cause further ischemia to the lung, so embolization in these cases is only warranted if hemoptysis is life threatening. Hence, the patient was put on medical conservative therapy to control recurrent hemoptysis instead of BAE. Hence, of the total 27 patients who were referred for BAE, preprocedural MDCT changed the management in 2 patients (7.4%).
DSA
Twenty-five bronchial arteries and 9 nonbronchial systemic arteries were found to be abnormal on angiography. When comparing the findings with MDCT, all the bronchial arteries were prospectively identified as abnormal by MDCT. Three of the arteries that were found to be abnormal on MDCT could not be evaluated on DSA. In 1 of these patients, DSA was not performed. The other 2 arteries (1 left intercostal and 1 right bronchial) could not be selectively catheterized and hence could not be evaluated. One nonbronchial artery (left lateral thoracic artery), which was found abnormal on MDCT, was found normal on DSA. Of 34 abnormal arteries, 33 arteries were embolized. One of the patients had sequestration, and, as described above, DSA in this patient was performed for diagnostic purposes only.
Of 25 patients in whom BAE was attempted, embolization could not be performed in 2 patients. In 1 of these patients, no abnormal vessel was found on either CTA or DSA. The diagnosis in this patient was active pulmonary tuberculosis, and the patient was treated with antitubercular therapy. In the second patient, we could not superselectively catheterize an abnormal right bronchial artery, which was identified on MDCT.
A total 25 bronchial arteries were embolized during the procedure. Of these 25 bronchial arteries, 4 bronchial arteries (16%) were not adequately visualized on flush aortogram. Of these bronchial arteries, 3 arteries were not visualized at all, and only parenchymal staining was seen, and, in the fourth case, only the distal part of the vessel was visualized ( Figure 5C ). The reason that they were inadequately visualized was that their origins were either anterior or posterior, and hence were not seen on frontal flush aortogram due to overlapping. However, due to prior knowledge of the anatomy on MDCT, selective catheterization could easily be done in all of these arteries.
Discussion
BAE is commonly used for treating massive hemoptysis. In addition, chronic recurrent mild and recurrent hemoptysis that disturbs the life style of the patient and is not amenable to surgical treatment also is increasingly being treated with BAE [7] . In patients with an episode of hemoptysis, finding the source and site of hemoptysis before the BAE procedure is very important and can direct a more focused and efficient procedure. Diagnostic studies for massive hemoptysis include radiography, bronchoscopy, and CT of the chest. CT is a useful method to identify and depict the bronchial artery and to predict the presence of nonbronchial systemic vessels that supply a parenchymal lesion. Therefore, depicting bronchial arteries with CT before performing interventional procedures could provide useful information and direction for bronchial arterial interventional procedures. In our study, we have made an attempt to evaluate the role of MDCT for diagnosis and management planning in patients with hemoptysis before BAE.
CT is a useful method to use to identify and depict the bronchial artery. Furuse et al [2] in 1987 first performed dynamic CT in patients with enlarged bronchial arteries. He showed that the mediastinal portion of bronchial arteries was successfully outlined as nodular or linear densities. MDCT has the advantage that it not only can detect but also can accurately depict the origin and course of bronchial arteries. A bronchial artery diameter larger than 2 mm was considered abnormal. In our study, a cutoff of 2 mm was taken as a diameter of abnormal bronchial arteries on MDCT. A diameter of abnormal right bronchial arteries ranged from 2.2-4.3 mm (mean, 2.9 mm), and abnormal left bronchial arteries ranged from 2-5 mm (mean, 2.9 mm). To our knowledge, there is only one other study that compared the diameter of abnormal bronchial arteries detected on MDCT with findings on angiography. Yoon et al [3] retrospectively reviewed MDCT in patients with hemoptysis who had undergone BAE, and, in their study, the diameter of bronchial arteries, which were abnormal on angiography, ranged from 1.3-4.7 mm (mean, 2.8 mm). Also, 8 bronchial arteries causing hemoptysis were <2 mm. However, in our study, a cutoff value of 2 mm on MDCT prospectively detected all abnormal bronchial arteries as detected later with DSA. There is only one other study that compared the diameter of abnormal bronchial arteries with findings on DSA.
We were able to demonstrate the origin and course of all the abnormal arteries up to the hilum. In addition, we also were able to detect and depict the course of bronchial arteries of ectopic origin. These branches, sometimes referred to as bronchial arteries of anomalous origin, were defined as arteries that originate from the descending aorta outside the T5-T6 level, with an intrapulmonary course along the major bronchi. In our study group, ostia of abnormal bronchial arteries, as depicted on CT, were orthotopic in 25 bronchial arteries (92.6%), whereas, it was ectopic in 2 bronchial arteries (7.4%) ( Figure 7E ). The reported prevalence of bronchial arteries with an anomalous origin ranges from 8.3%-35% [8, 9] . Remy et al [10] demonstrated 4 of 23 right arteries (17%) and 8 of 30 left arteries (27%) as ectopic on CT angiograms. In their retrospective study, Yoon et al [3] depicted 5 bronchial arteries (9.6%) as ectopic on CT. None of these arteries were selectively catheterized during DSA. It highlights the importance of knowing the presence of ectopic bronchial arteries before intervention. In our study, 2 abnormal ectopic arteries were found on CTA, both of them were easily catheterized by using CT information and embolized. Thus, the anatomic information provided by CT angiograms helped in the guidance of successful catheterization and rapid embolization of orthotopic as well as ectopic bronchial arteries.
The origin of 16 of 17 right bronchial and intercostobronchial arteries (94.2%) was from medial wall ( Figure 1C ), and 7 of 10 left bronchial arteries (70%) were from the anterior wall of aorta ( Figure 2C ). Our study confirmed the findings that the majority of right bronchial arteries arise in the medial wall of the descending aorta, whereas most left bronchial arteries arise in the anterior wall of the descending aorta [2, 3, 10] .
One of the major causes of recurrent hemoptysis after successful embolization of bronchial arteries is the presence of abnormal nonbronchial systemic arteries. We identified nonbronchial systemic arteries in 11 of 27 patients (40.7%) (Figures 4, 5) . Three of these patients (11.1%) had normal bronchial arteries, and a nonbronchial systemic artery was the only source of hemoptysis. In a study by Goh et al [11] of 103 patients who underwent BAE, 42 had nonbronchial systemic contributions (41%) and 12 had abnormal nonbronchial systemic arteries but normal bronchial arteries (11.7%). Wong et al [12] found that nonbronchial collateral vessels supplied the bleeding area in 14 of 16 patients with life-threatening hemoptysis (88%). In 3 of those 16 patients (19%), bleeding from systemic vessels other than the bronchial arteries was the only source of hemoptysis. Vujic et al [13] controlled hemoptysis in 3 patients by embolizing only the intercostal arteries. In the study by Hashimoto et al [14] , massive hemoptysis was caused by internal mammary artery contributions to the perfusion of lesions in 5 of 13 patients. Thus, our study also corresponds with these studies and confirms the significant contribution of nonbronchial systemic arteries in patients with hemoptysis. Embolization of the nonbronchial systemic arterial supply can lower the immediate recurrence rate after successful embolization. Therefore, it is important to identify these abnormal nonbronchial systemic arteries before embolization.
MDCT angiography also can depict the course and origin of an abnormal vessel. Yoon et al [3] also reported abnormal nonbronchial systemic arteries in 8 of their 22 patients when using MDCT (36.7%). Exploration of all nonbronchial systemic arteries to find an abnormal artery followed by selective catheterization and embolization is a difficult job and takes a long time. The procedure time can be critical, especially in life-threatening situations. Moreover, a long procedure time will add to the patient's radiation exposure and increase the likelihood of iatrogenic and procedure-related complications. Hence, depiction and detection of abnormal nonbronchial systemic arteries with the use of MDCT before the procedure will help to concentrate on the relevant artery. Knowing its anatomy, that is, its origin and course with the help of 3-dimensional reconstructions will help in selective catheterization of these arteries. In our study, of 11 nonbronchial arteries that were found to be abnormal on MDCT, 10 were easily catheterized, and 8 of them were embolized during the procedure. Remy et al [10] also reported that, in 3 of their patients that recurred, direct selective catheterization and embolization of nonbronchial systemic arteries were performed with the help of CT angiographic findings. Thus, MDCT and CTA are helpful for focused and efficient nonbronchial systemic artery catheterization and embolization.
Along with the evaluation of systemic arteries, MDCT also evaluates pulmonary vasculature. Although in 95% of cases of hemoptysis, the systemic arterial system is the origin of the bleeding [15] , pulmonary circulation can be the source of hemoptysis in approximately 5% of cases. Detecting pulmonary circulation as a source of hemoptysis before an interventional procedure changes the approach altogether. Various causes of hemoptysis due to pulmonary circulation include pulmonary emboli, Rasmussen aneurysm, direct invasion by neoplastic disease, and rare causes such as Dieulafoy's disease, and pulmonary arteriovenous malformation. In 1 of our patients, chronic pulmonary thromboembolism was detected on MDCT (Figure 9 ), which was previously unsuspected. The patient had been treated being a case of right lower lobe fibrosis due to the sequelae of tuberculosis based on findings of his previous HRCT of the chest.
Results of previous studies also have shown that there are chances of ischemic complication to the lung when embolization of the systemic supply is attempted in the presence of pulmonary artery occlusion [16] due to any cause. Embolization has been described in cases of chronic pulmonary thromboembolism [16] , but it is only justified in cases of life-threatening hemoptysis. A decision was made to put the patient on conservative therapy. Thus, MDCT helped in the diagnosis of a pulmonary cause when it was previously unsuspected and helped in the proper management of the patient. MDCT not only detected the pulmonary embolism, but it also accurately demonstrated an extensive collateral supply. Due to the presence of extensive collaterals, embolization is difficult in these situations. MDCT, by displaying the hypertrophied collaterals before the procedure, can certainly help in planning of embolization and can add to the efficiency of the procedure.
MDCT is helpful, not only in the detection and depiction of bronchial and nonbronchial systemic arteries causing hemoptysis, but also for a diagnosis of alternate sources, such as anomalous vessels seen in congenital anomalies. One of our patients had an abnormal vessel that supplied a normal segment of the left lower lobe (Figure 8 ). MDCT accurately displayed the abnormal vessel. In addition, it also provided other necessary information for a complete diagnosis of this patient, namely dilated pulmonary vein ( Figure 8D ), suggestive of its normal drainage, absence of pulmonary artery supply in the segment ( Figure 8E ) supplying by the vessel, and absence of any lung parenchymal abnormality in the involved segment ( Figure 8C ). This entity is classified under type 1 intralobar sequestration (purely vascular sequestration) in the classification suggested by Pryce [17] . Although we performed diagnostic angiography in this patient, MDCT had provided all necessary information for diagnosis, and, hence, the invasive procedure could be avoided for diagnosis in these conditions. Preliminary flush thoracic descending aortogram was obtained in all the patients. It is useful to identify the number and the origin sites of bronchial arteries from the aorta to determine the optimal angiographic approach. In our study, 4 of 25 abnormal bronchial arteries (16.0%) were not seen in flush anteroposterior aortogram; however, all of these vessels were selectively catheterized and embolized with the help of findings of CTA ( Figure 5 ), so oblique flush aortograms were not required to localize these arteries. Phillips and Ruttley [18] showed that a descending thoracic aortogram is useful in the detection of bronchial and nonbronchial systemic arteries that supply parenchymal lesions. However, CTA in our study was able to demonstrate all abnormal nonbronchial systemic arteries. Hence, CTA can replace the routine use of preliminary flush aortography before BAE for determining the number and site of abnormal arteries. Remy et al [10] also suggested that, thoracic aortography, an invasive procedure still recommended by many researchers to improve the detection of arteries that are contributing to hemoptysis, should be replaced with CTA.
We embolized all 25 abnormal bronchial arteries (15 on the right and 10 on the left). Apart from bronchial arteries, we also embolized 8 nonbronchial arteries. Embolic materials that we used were PVA particles (400-600 mm or 500-700 mm) alone or with Gelfoam, Embosphere (500-700 mm), and coil (size 35-3-4). The majority of our cases were done by using PVA particles alone. Three of our patients developed chest pain, and 1 developed fever, which subsided within 5 days with conservative treatment. Most dreaded of the complications is paraparesis due to spinal cord ischemia. Therefore, the presence of an anterior spinal artery should be carefully scrutinized. Inadvertent embolization of this artery may cause spinal cord ischemia and resultant paraplegia.
One of our patients showed an anterior spinal artery on DSA; however, we failed to visualize an anterior spinal artery on MDCT images ( Figure 10 ). In their retrospective study, Remy et al [10] also searched for an anterior spinal artery on curved maximum intensity projections at the cervicothoracic junction but failed to visualize any on either MDCT or angiography, hence, they could not draw any conclusion regarding the ability of MDCT to identify anterior spinal artery. We also could not see this artery on MDCT, which shows that MDCT may not be so sensitive to detect these arteries. However, further studies may be needed to draw any conclusion. Immediate control of bleeding was achieved in 22 of 25 patients (88%) in whom BAE was attempted. Technical success could not be achieved in 2 patients. In 1 of the patients, we could not achieve a secure selective position for embolization, and, in another patient, no hypertrophied artery was visualized.
There were some limitations of this study. First, measurement of radiation dose and fluoroscopy time during the intervention procedure was not done, because this was not the primary aim of this study. However, studies can be designed in the future to compare these 2 variables in a subgroup of patients with and without the use of MDCT before the BAE procedure. Second, patients with significant hemodynamic compromise were not offered MDCT before the BAE procedure to save time before the intervention. However, we would like to mention that the CTA does not need to be performed on the same day as the BAE. A CTA within the past 1-4 months is adequate for embolization planning, and, in fact, respirologists should be encouraged to order CTA early in the evaluation of any patient with hemoptysis who also is in need of a diagnostic CT, so that the ''map'' is ready if or when an urgent procedure becomes necessary.
Thus, by detecting and depicting all abnormal bronchial and nonbronchial arteries, MDCT and CTA helped in the planning of the embolization procedure (regarding hardware selection such as the choice of catheter type and size, and the amount of embolization material) depicted the anatomy of thoracic vasculature, which was found very helpful for interventional radiologist and, hence, has the potential to decrease the procedure time and radiation exposure to patient. This resulted in increase in the overall efficiency of the procedure. Moreover, by diagnosing the uncommon causes of hemoptysis and status of pulmonary vasculature before the intervention, MDCT guided in further management of patient. So, we recommend routine use of MDCT before interventional procedure in all patients of hemoptysis. MDCT can replace the routine use of preliminary flush aortography before BAE for determining the number and site of abnormal arteries. Although we failed to detect an anterior spinal artery in 1 of the patients, where we found it on DSA; further studies are needed to know about the sensitivity of MDCT in detection of these arteries.
Clinical Impact
Although there is a lack of prospective studies to evaluate the role of CTA before BAE in patients with hemoptysis, our preliminary experience suggests that MDCT, by providing a detailed road map of abnormal vasculature, valuable information regarding pulmonary vasculature and detecting uncommon causes of hemoptysis, including congenital anomalies, has the potential to increase the overall efficiency of the embolization procedure with a decrease in procedure time and complication rates. As shown in our series, MDCT guides and changes the management in a certain number of patients. We also suggest that aortography is not necessary after CTA, and it only results in delay, radiation, and contrast use.
